-
Lorlatinib, sold
under the
brand name
Lorbrena in the
United States, Canada, and ****an, and
Lorviqua in the
European Union, is an anti-cancer drug developed...
- who
relapse can then be
treated with the third-generation ALK
inhibitor lorlatinib. Up to 5% with
NSCLC have
overactive MET,
which can be
inhibited with...
- brigatinib, clobazam, dabrafenib, elagolix, eslicarbazepine, letermovir,
lorlatinib, oritavancin, perampanel, telotristat.
Click on genes,
proteins and metabolites...
-
Insmed mycobacterial lung
disease Emicizumab-kxwh
Genentech hemophilia Lorlatinib Pfizer ALK-positive,
metastatic non-small cell lung
cancer Brentuximab...
-
Binimetinib Cobimetinib Selumetinib Trametinib EML4-ALK
Crizotinib Entrectinib Lorlatinib Bruton's
Acalabrutinib Ibrutinib Pirtobrutinib Zanubrutinib...
-
Binimetinib Cobimetinib Selumetinib Trametinib EML4-ALK
Crizotinib Entrectinib Lorlatinib Bruton's
Acalabrutinib Ibrutinib Pirtobrutinib Zanubrutinib...
-
Crizotinib L01ED02
Ceritinib L01ED03
Alectinib L01ED04
Brigatinib L01ED05
Lorlatinib L01EE01
Trametinib L01EE02
Cobimetinib L01EE03
Binimetinib L01EE04 Selumetinib...
-
common G1202R
mutation that
provides resistance to alectinib. Pfizer's
lorlatinib was the
first third-generation
inhibitor and was
approved in 2018 by the...
- to test the drug in
patients with ROS1/NTRK/ALK gene rearrangements.
Lorlatinib (also
known as PF-06463922) was
shown in an
ongoing Phase 2
clinical trial...
-
generation targeted therapy (trial drug X-396),
manufactured by XCovery.
Lorlatinib is a
third generation targeted therapy (FDA
approved in 2018), manufactured...
